Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
MEK Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
MEK Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Mitogen-activated protein kinases are a family of enzymes that has an important role in regulating the physiological processes in mammalian cells and tissues. These play a significant role in signal transduction by modulating gene transcription in the nucleus in response to the changes in the cellular environment. Mitogen is a substance- protein or peptide or anything else that induces mitosis in a cell or enhances the rate of mitosis like Glucose, Glycerol, Cytokinins etc. There are 11 members of the MEK superfamily. Various MEK isoforms are present that are specific to their substrates. These link extracellular signals to the intracellular signals that regulate growth, apoptosis, migration and proliferation, cell cycle progression, metabolism, cell adhesion, motility and more. MEKs have been seen to be associated with the pathogenesis of various types of cancers i.e. Prostate cancer, Colon cancer, Lung cancer and more. These have also been associated with the pathogenesis of various neurodegenerative disorders like Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis (ALS) and others. Therefore, inhibiting it might be an approach to slowing down the progression of these diseases. Research is being conducted globally to discover new and novel molecules to be used as anti-IL-23 agents. The development and launch of new products will thus increase the revenue of the market in the forecasted years. For instance, according to the American Cancer Society, there are on average 2000 – 4500 newly diagnosed lung carcinoid tumors in the USA wherein lung carcinoid cancers account for about 1% to 2% of all carcinoid cancers.
A number of these inhibitors are in the market while many are in ongoing clinical trials. 51 companies have various products in their pipelines with 322 products in various stages of clinical trials. 3 products are in Phase 4, 3 in Phase 3, 16 in Phase 2 and 11 in Phase 1 of the clinical trials.
Key Developments of MEK Inhibitors
Approved molecules of MEK Inhibitors
Drugs In The Pipeline Of MEK Inhibitors
Clinical Activity and Developments of MEK Inhibitors
As of June 2023, various companies have approximately 51 MEK for 322 diseases. For these diseases, many trials are being conducted by players globally. For instance,
|
Molecule name |
Number of studies |
|
Mekinist (trametinib) |
282 |
|
Mektovi (binimetinib) |
131 |
|
Zepsun (donafenib) |
48 |
|
Koselugo (selumetinib) |
137 |
|
Cotellic (cobimetinib) |
116 |
MEK inhibitors are advanced anti-cancer medications that selectively target the MAPK pathway. These drugs, such as Mekinist (trametinib), Mektovi (binimetinib), and Zepsun (donafenib), have been approved for the treatment of BRAS and NRAS-Mutant melanoma cell lines. However, their potential extends far beyond that. They are currently undergoing pre-clinical and clinical trials for a wide range of indications, including various types of carcinoid tumors like lung carcinoid tumors, sarcomas, respiratory tract diseases and neoplasms, lung neoplasms, nevus pigmented, adenocarcinoma and more. The clinical trials have shown promising results, and many regulatory agencies have granted approval for various indications globally.
Novartis’s Tafinlar (dabrafenib) with Mekinist (trametinib) combination had net sales of $1770 million in the financial year 2022 which was 5% higher than the net sales in the financial year 2021. It has net sales of $465 million in the 4th quarter of 2022 which was 2% higher than the net sales in the 4th quarter of 2021. Pfizer’s Mektovi (binimetinib) had net sales of $176 million in the financial year 2022 which was 14% higher than the last year’s net sales globally. Out of $176 million in sales in 2022, $175 million in sales was from the USA itself. The drugs are prescribed in combination regimens driving the sales of all the drugs given together to the patient. According to the Alzheimer’s Association, in 2023 more than 6 million Americans are living with Alzheimer’s disease and about 1 in 9 people age 65 and above have Alzheimer’s. It is projected that by 2050, the number would grow to 12.7 million patients. Therefore, there is an opportunity for the market players to generate revenues by launching new treatment drugs and regimens.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Mekinist (trametinib), Mektovi (binimetinib) and Zepsun (donafenib) are approved by various regulatory agencies.
These are being used in the treatment of BRAS and NRAS-Mutant melanoma cell lines. These are in the clinical trials for various other indications like Carcinoid tumors, Nevus pigmented, Adenocarcinoma and others
Novartis (Switzerland), Merck (MSD) (USA), AstraZeneca Inc. (USA), Ono Pharmaceutical Co., Ltd (Japan) and Pierre Fabre (France) are some of the major market players for MEK Inhibitors.
Rising incidence of diseases improvement in technologies, development of new treatment lines in the market and changing lifestyles leading to various kinds of cancers and neurodegenerative disorders are the key opportunities for MEK Inhibitors in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.